Rapport Therapeutics RAPP 深 滬
等待開盤 05-27 09:30:00 美东时间
39.71
+1.990
+5.28%
華盛通- 最 高40.40
- 今 開38.35
- 成交量 43.81万股
- 最 低 37.67
- 昨 收 37.72
- 總市值 18.99亿
- 52周最高 42.2685
- 市盈率 靜 --
- 換手率 0.92%
- 52周最低 8.195
- 委 比 -35.14%
- 總股本 4782.69万
- 歷史最高 42.2685
- 量 比 1.64
- 振 幅 7.24%
- 歷史最低 6.43
- 每 手 1
- 風險率 7.95%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多药物受理最新动态：Rapport Therapeutics, Inc.RAP-219片进口申请获受理
国家药品监督管理局药品审评中心数据显示，2026年5月26日，Rapport Therapeutics, Inc.的RAP-219片申请已获受理，受理号为JX...
05-26 17:15
美股大行评级 | 英伟达绩后获11家大行集体上调目标价；劳氏、ELF、Intuit、VF等惨遭多家大行下调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx药业"超配"评级，目标价从84美元升至96美元；Ascendiant Capital：维持Liqtech国际"买入"评级，目标价从4.3美元升至4.4美元
05-22 10:18
美股大行评级 | 最高1100美元，花旗、瑞穗、 Melius Research齐上调美光目标价；X-Energy获大小摩等多家机构首予“买入”评级
今日重点评级关注：TD Cowen：维持Strategy"买入"评级，目标价从395美元升至400美元；摩根士丹利：维持Cipher Digital"超配"评级，目标价从40.5美元升至42.5美元
05-20 11:55
Truist Securities Assumes Rapport Therapeutics at Buy, Raises Price Target to $56
Truist Securities analyst Danielle Brill assumes Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and raises Price Target to $56.
05-20 02:32
美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
BTIG Reiterates Buy on Rapport Therapeutics, Maintains $53 Price Target
BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $53 price target.
05-08 18:34
Rapport Therapeutics, Inc. (RAPP) Gets a Buy from JonesTrading
JonesTrading analyst Justin Walsh reiterated a Buy rating on Rapport Therapeuti...
05-08 04:36
Rapport Therapeutics Q1 EPS $(0.42) Beats $(0.65) Estimate, Sales $20.000M Beat $8.571M Estimate
Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.65) by 35.38 percent. This is a 38.24 percent increase over losses of $(0.68) per share
05-07 20:40
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
Rapport Therapeutics reported positive Phase 2a follow-up data for RAP-219 in focal onset seizures (FOS), showing a 90% median reduction in clinical seizures over baseline. The Phase 3 program for FOS remains on track to begin in Q2 2026. Bipolar mania Phase 2 trial results are now expected in Q4 2026, ahead of previous guidance. RAP-219's long-acting injectable formulation and other pipeline programs are advancing. The company entered a collabor...
05-07 11:00
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
Rapport Therapeutics will present Phase 2a results for RAP-219, a potential first-in-class TARPγ8-specific AMPA receptor negative allosteric modulator, at the 2026 AAN Annual Meeting. The presentation will highlight efficacy and tolerability data in patients with focal onset seizures, with potential applications in epilepsy, bipolar disorder, and chronic pain. RAP-219 targets brain regions linked to seizures while minimizing hindbrain activity, o...
04-01 11:00
